TLSI Stock Forecast: TriSalus Life Sciences, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering TriSalus Life Sciences, Inc. hold a median 12-month price target of $6 — +158.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 34 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores TriSalus Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (79): Sales and profits are climbing, and climbing faster than before.
Accruals (23): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TLSI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TLSI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +158.6% from it.
Of the 19 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Nov 2026 | Canaccord Genuity | Maintains | Buy | $7.00 → $4.00 |
| 11 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $12 → $10 |
| 23 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $11 → $12 |
| 9 Sept 2026 | HC Wainwright & Co. | Initiates | Buy | $11 |
| 13 May 2026 | Lake Street | Maintains | Buy | $10 → $8.00 |
| 9 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 17 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
| 28 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 13 Feb 2025 | Lake Street | Initiates | Buy | — |
| 24 Jan 2025 | Roth MKM | Reiterates | Buy | — |
| 17 Dec 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 15 Nov 2024 | Canaccord Genuity | Maintains | Buy | — |
| 11 Nov 2024 | Roth MKM | Initiates | Buy | — |
| 25 Oct 2024 | Northland Capital Markets | Initiates | Outperform | — |
| 16 Sept 2024 | Oppenheimer | Initiates | Outperform | — |
| 27 June 2024 | Canaccord Genuity | Maintains | Buy | — |
| 30 May 2024 | Canaccord Genuity | Initiates | Buy | — |
| 10 May 2024 | JonesTrading | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TLSI.
This page is one stock. Monday covers all of them.
TLSI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TLSI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, TriSalus Life Sciences, Inc. returned −53.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TLSI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.1×
- Price / book
- 210.9×
- EV / EBITDA
- —
Cheaper than 36% of US stocks
Cheaper than 1% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 86.8%
- Operating margin
- −63.0%
- Net margin
- —
Higher than 95% of US stocks
Higher than 17% of US stocks
- Return on equity
- —
- Return on assets
- −38.8%
- Dividend yield
- —
Higher than 11% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
TriSalus Life Sciences, Inc. has a market value of $143.1M and an enterprise value of $135.8M.
Revenue in the twelve months to 30 June 2026: $45.1M. The latest quarter grew 1.7% year on year.
Net income over the same four quarters: −$28.2M, a −62.6% net margin.
Diluted earnings per share, trailing twelve months: −$1.30.
Free cash flow in the twelve months to 30 June 2026: −$23.3M.
TriSalus Life Sciences, Inc. employs 102 people — $442K of revenue per employee.
Data provided by Twelve Data
TLSI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TLSI’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own TriSalus Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TLSI
What is the TLSI stock price forecast for 2026-2027?
The 4 Wall Street analysts covering TriSalus Life Sciences, Inc. have a median 12-month price target of $6, with estimates ranging from $4 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TLSI stock a buy right now?
Of the 4 analysts covering TriSalus Life Sciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TriSalus Life Sciences, Inc. 34 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TLSI?
As at 21 Nov 2026, TriSalus Life Sciences, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).
Will TLSI stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +158.6% from the last close, and Ticker Nerd's factor model ranks TriSalus Life Sciences, Inc. 34 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TLSI stock forecast for 2030?
No analyst covering TriSalus Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $14 over the next 12 months.
How has TLSI stock performed over the past year?
TriSalus Life Sciences, Inc. returned -53.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does TriSalus Life Sciences, Inc. do?
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers. Its current product portfolio centers on Pressure-Enabled Drug Delivery (PEDD) platforms, including the TriNav infusion system for hepatic arterial procedures and the Pancreatic Retrograde Venous Infusion device.
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers. Its current product portfolio centers on Pressure-Enabled Drug Delivery (PEDD) platforms, including the TriNav infusion system for hepatic arterial procedures and the Pancreatic Retrograde Venous Infusion device. TriSalus also advances nelitolimod, an investigational immunotherapeutic designed to work alongside standard treatments in solid tumors. The company’s products and clinical programs are aimed at improving how therapies reach tumor sites, particularly where conventional delivery faces anatomical and physiological barriers. TriSalus Life Sciences, Inc. serves the interventional oncology and medical device markets, combining device-based delivery with oncology therapeutics to support physicians treating liver cancer, liver metastases, and pancreatic tumors.
CEO Ms. Mary T. Szela B.S.N., M.B.A. · 102 employees · United States · https://trisaluslifesci.com